GenSight Biologics
Develops innovative therapies for mitochondrial and neurodegenerative diseases.
Launch date
Employees
Market cap
AUD67.7m
Enterprise valuation
AUD95m (Public information from Sep 2024)
Share price
€0.376 SIGHT.PA
Company register number 751164757
Paris Île-de-France (HQ)
Authorizing premium user...